Chiral Bioequivalence
Authors:
- Joseph P. BoniJBJoseph P. Boni
- Joan M. KorthbradleyJKJoan M. Korthbradley
- 1 December 2000
- journal article
- clinical trial
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 39 (6) , 459-469
Abstract
For many racemic drugs, bioequivalence assessment based on isomer-nonspecific assays is appropriate because enantiomeric area under the concentration-time curve (AUC) exposure ratios are close to unity. Use of nonspecific methods in cases in which the ratio is substantially greater or less than 1, however, may obscure real therapeutic differences among formulations, especially if the enantiomers exhibit differing pharmacological potencies. To examine the influence of absorption rate on etodolac bioequivalence as measured by total [(R,S)-] and (S)-etodolac. Single dose, 3-period, crossover, pharmacokinetic study in 24 healthy volunteers in which the administration rate of etodolac was varied. Participants received etodolac 400mg in solution, given as a single dose over 1 minute or as divided doses over 30 and 90 minutes. Unresolved and enantiomer concentrations of etodolac were measured by a validated HPLC assay. The enantiomer ratio was similarly measured by HPLC. Bioequivalence parameters derived for both unresolved and (S)-etodolac indicate that peak plasma drug concentration (Cmax) was not bioequivalent. By delaying absorption, bioequivalence was lost. Collectively, these data demonstrate that bioequivalence between 2 products of etodolac based on enantiomerically nonspecific criteria alone may not generalise to the pharmacologically relevant (S)-enantiomer. This suggests that enantiospecific assays are necessary for bioequivalence assessments.Keywords
This publication has 31 references indexed in Scilit:
- Bioequivalence of Chiral DrugsClinical Pharmacokinetics, 1997
- Enantioselective Assays in Comparative Bioavailability Studies of Racemic Drug Formulations: Nice to Know or Need to Know?The Journal of Clinical Pharmacology, 1996
- Simultaneous First‐Order and Capacity‐Limited Elimination Kinetics After Oral Administration of VerapamilThe Journal of Clinical Pharmacology, 1996
- Etodolac Clinical PharmacokineticsClinical Pharmacokinetics, 1994
- Stereoselective, competitive, and nonlinear plasma protein binding of ibuprofen enantiomers as determinedin vivo in healthy subjectsJournal of Pharmacokinetics and Biopharmaceutics, 1993
- The Stereoselective Pharmacokinetics of Etodolac in Young and Elderly Subjects, and After CholecystectomyThe Journal of Clinical Pharmacology, 1992
- Bioequivalence of Racemic DrugsThe Journal of Clinical Pharmacology, 1992
- Comparative Pharmacokinetics of Unbound Disopyramide Enantiomers following Oral Administration of Racemic Disopyramide in HumansJournal of Pharmaceutical Sciences, 1991
- The relationship between the pharmacokinetics of ibuprofen enantiomers and the dose of racemic ibuprofen in humansBiopharmaceutics & Drug Disposition, 1990
- A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailabilityJournal of Pharmacokinetics and Biopharmaceutics, 1987